En Español
If you were prescribed the drug Xarelto, your life may have been placed at risk. The drug Xarelto, manufactured by Bayer, has been linked to cranial and gastrointestinal bleeding when taken once per day. Bellwether trials for those hurt by the drug are expected to begin in 2017.
Judge Eldon E. Fallon of the U.S. District Court for the Eastern District of Louisiana stated that bellwether trials in the multi-district litigation surrounding Xarelto will begin in early 2017. The selection and scheduling process is currently underway.
The litigants claim that the manufacturers of Xarelto, Bayer and Janssen failed to warn patients of the bleeding risks. They further claim that the risks are reduced if Xarelto is taken twice per day and is properly monitored.
40 cases have been selected to participate in the bellwether trials before the main cases reach federal courtrooms. The purpose of bellwether trials is to see how juries will respond to the evidence presented in the case.
So far, the first four cases have been scheduled for hearings. Respectively, the first and second cases will be heard on February 6 and March 17, 2017. They are scheduled for the U.S. District Court for the Eastern District of Louisiana.
The third and fourth cases are scheduled for April 24 and May 30th in federal district courts to be determined. The courts will be located in Mississippi and Texas. However, the specific cases for the first four bellwether dates have yet to be selected. In addition, the locations for the latter two cases are subject to change.
In addition to the bellwether trials taking place, more than 800 lawsuits, most involving out-of-state litigants, will be heard in Philadelphia’s Complex Litigation Center.
If you have been prescribed the drug Xarelto and suffered an adverse health event such as cranial or gastrointestinal bleeding, you may be entitled to compensation. Contact the “Strong Arm” attorneys at John Foy & Associates. Our attorneys may be able to get you the compensation you deserve. Contact us today.
